MapLight Therapeutics, Inc.

Exciting news! 🔬 We've revamped the science section of our website, where you can learn more about our platform. https://lnkd.in/e8HaHkHH

This Alzheimer's and Brain Awareness Month 🧠, we're proud to contribute to the fight against Central Nervous System (CNS) disorders. Central to this work is our focus on Alzheimer's disease psychosis. At MapLight, we're committed to research that may lead to new treatment options for patients. Learn more: https://lnkd.in/d5wESj-M #AlzheimersAwareness #BrainHealth #CNSResearch

The number of Americans being diagnosed with Alzheimer's is growing each year – MapLight is dedicated to better understanding Alzheimer's Disease Psychosis and building on the existing body of research to find potential new treatments. Learn more about our work. https://lnkd.in/d5wESj-M

One in six U.S. adults lives with a mental illness. With Mental Health Awareness month soon coming to a close, we want to affirm our commitment to understanding more about mental health and supporting people living with these conditions each day. Learn more about our work in this space via our website. https://lnkd.in/gWgc-BdZ

Today marks World Schizophrenia Day. Did you know that schizophrenia affects 24 million people worldwide? We are working to develop potential new treatment options for people with schizophrenia. Stay up to date on our work by visiting our website. https://lnkd.in/gWgc-BdZ

MapLight's Dr. Anatol Kreitzer will participate in the 35th WORLD CONGRESS by the Collegium Internationale Neuro-Psychopharmacologicum this coming Saturday, May 25. In his co-presentation – titled: "Identifying and Fixing Dysfunctional Circuits in Depression: Leveraging Systems Neuroscience and Translational Approaches for Developing Novel Targets and Therapeutics" – he will discuss the latest programs at Maplight, including two programs in the development of novel therapeutics for depression. Learn more. https://lnkd.in/dnrP3KNN

This past Saturday, the MapLight Therapeutics, Inc. team was proud to step up for people with mental illness by being part of the Boston-area NAMIWalks event. With over 1,500 participants and 126 teams walking, this event was incredibly impactful.    We are already looking forward to participating next year. Learn more about the event: https://lnkd.in/gpEATKgJ

We're thrilled to announce the opening of our new Boston-area office. This expansion marks a significant milestone in our company's journey. Stay tuned for updates as we continue to grow. www.maplightrx.com

The MapLight Therapeutics, Inc. team was privileged to be invited to and attend the Schizophrenia & Psychosis Action Alliance Inaugural SPRING Summit. It's an honor to contribute to the collective effort aimed at accelerating new treatments and improving access for people with schizophrenia.    Pictured is MapLight’s Charmaine Lykins and Kimberly Thompson, along with Peter Weiden, MD.   Learn more about the Alliance’s work via their website. https://sczaction.org

Today’s SPRING Summit included a terrific panel discussion featuring a person living with schizophrenia, a clinician, a family member and judges from both civil and criminal courts. Each brought valuable perspectives about the gaps in care for people with this severe brain disease and the types of programs and services that could bridge those gaps. Working together, we will create a Roadmap for Recovery! #SPRINGSummit